How does Cresemba (isavuconazole) compare to other antifungal agents?

Cresemba (Isavuconazole) Compared to Other Antifungal Agents

Cresemba (isavuconazole) is non-inferior to voriconazole for invasive aspergillosis and offers a superior safety profile with significantly fewer drug-related adverse events, hepatotoxicity, visual disturbances, and drug-drug interactions, making it a preferred first-line option in many clinical scenarios. 1, 2

Efficacy Comparisons

Invasive Aspergillosis

• Isavuconazole demonstrated non-inferiority to voriconazole in the landmark SECURE trial, with all-cause mortality at day 42 of 19% versus 20% (adjusted difference -1.0%, 95% CI -7.8 to 5.7), meeting the pre-specified non-inferiority margin. 1
• The 2025 American Thoracic Society guidelines now recommend either voriconazole or isavuconazole as first-line monotherapy for invasive pulmonary aspergillosis, with isavuconazole particularly suitable when drug interactions or tolerability concerns exist. 3
• Meta-analysis confirms comparable mortality outcomes between isavuconazole and other antifungal agents (OR 1.11,95% CI 0.82-1.51). 2

Mucormycosis

• Isavuconazole is strongly supported as first-line therapy for mucormycosis, representing an alternative to liposomal amphotericin B, especially in patients with renal impairment. 4
• The 2019 global mucormycosis guideline provides moderate-strength recommendation for isavuconazole as first-line treatment, with median treatment duration of 84 days in clinical trials. 4
• Isavuconazole is strongly recommended for salvage therapy when liposomal amphotericin B fails or is not tolerated. 4

Invasive Candidiasis

• Isavuconazole failed to demonstrate non-inferiority to caspofungin in the ACTIVE trial for candidemia, with successful response rates of 60.3% versus 71.1% (adjusted difference -10.8%, 95% CI -19.9 to -1.8). 5
• However, in vitro data shows isavuconazole has potent activity against Candida species (MIC₅₀ 0.004 mg/L), superior to voriconazole (0.03 mg/L) and itraconazole (0.008 mg/L). 6
• Isavuconazole is not recommended as first-line therapy for invasive candidiasis based on current evidence. 5

Safety Profile Advantages

Hepatotoxicity

• Isavuconazole causes significantly less hepatotoxicity than voriconazole, with hepatobiliary disorders occurring in 9% versus 16% of patients (p=0.016). 1
• Meta-analysis demonstrates reduced incidence of hepatic function abnormalities with isavuconazole in both treatment (OR 2.31,95% CI 1.41-3.78) and prophylaxis settings (OR 3.63,95% CI 1.31-10.05). 2
• In prophylaxis studies, premature discontinuation due to hepatotoxicity was 5.3% with isavuconazole versus 22.8% with voriconazole (p=0.0002). 7

Visual and Dermatologic Effects

• Eye disorders occurred in 15% of isavuconazole patients versus 27% with voriconazole (p=0.002). 1
• Skin and subcutaneous tissue disorders were less frequent with isavuconazole (33% versus 42%, p=0.037). 1

Overall Tolerability

• Drug-related adverse events occurred in 42% with isavuconazole versus 60% with voriconazole (p<0.001). 1
• Premature discontinuation rates were significantly lower with isavuconazole (14.7% versus 43.8%, p<0.0001). 7
• Discontinuation rates in treatment settings showed isavuconazole was superior (OR 1.96,95% CI 1.26-3.07). 2

Drug Interaction Profile

Contraindications

• Isavuconazole is contraindicated with strong CYP3A4 inhibitors (ketoconazole, high-dose ritonavir ≥400mg q12h) and strong CYP3A4 inducers (rifampin, carbamazepine, St. John's wort, long-acting barbiturates). 8
• This represents a narrower contraindication profile compared to voriconazole's extensive drug interaction list. 9

Clinical Impact

• In prophylaxis settings, isavuconazole required less frequent discontinuation due to drug-drug interactions compared to voriconazole (p=0.002). 7

Prophylaxis Efficacy

Hematopoietic Cell Transplant

• Isavuconazole provided comparable prophylaxis efficacy to voriconazole in allogeneic HCT recipients, with invasive fungal infection rates of 3.2% versus 2.9% (p=0.881). 7
• Median duration of prophylaxis was longer with isavuconazole (94 days versus 76 days, p<0.0001) due to better tolerability. 7
• All-cause mortality at day +180 was similar (6.3% versus 2.4%, p=0.089). 7

Acute Myeloid Leukemia

• Isavuconazole demonstrated effective prophylaxis with comparable breakthrough infection rates to voriconazole. 9
• Significantly fewer discontinuations occurred due to transaminase elevations (p=0.019), visual disturbances (p=0.002), and drug interactions (p=0.002). 9

Special Considerations

QT Interval Effects

• Isavuconazole uniquely shortens the QTc interval in a concentration-dependent manner, contrasting with other azoles that prolong QT. 8
• Contraindicated in patients with familial short QT syndrome. 8

Infusion-Related Reactions

• Infusion-related reactions (hypotension, dyspnea, chills, dizziness, paresthesia) can occur with IV administration; infuse over minimum 1 hour through 0.2-1.2 micron in-line filter. 8

Pregnancy Risk

• Isavuconazole may cause fetal harm with increased perinatal mortality and skeletal abnormalities in animal studies at doses below human maintenance doses. 8
• Contraception required during treatment and for 28 days after final dose. 8

Clinical Algorithm for Agent Selection

For Invasive Aspergillosis:

• First-line: Isavuconazole or voriconazole monotherapy 3
• Choose isavuconazole when: renal impairment present, significant drug interactions anticipated, history of voriconazole intolerance, or visual disturbances unacceptable 1, 2
• Consider combination with echinocandin in critically ill patients or suspected triazole resistance 3

For Mucormycosis:

• First-line: Liposomal amphotericin B or isavuconazole 4
• Choose isavuconazole when: renal dysfunction present or amphotericin B contraindicated 4
• Salvage: Switch to alternate class if primary therapy fails 4

For Invasive Candidiasis:

• Do not use isavuconazole as first-line therapy; prefer echinocandins 5
• May consider for salvage in azole-susceptible isolates 6

For Prophylaxis:

• Isavuconazole preferred over voriconazole in HCT and AML patients due to superior tolerability and lower discontinuation rates 7, 9